The novel oral PDE4 inhibitor, ibudilast, has been investigated for treatment of airway mucus hypersecretion and postnasal drip syndrome (PNDS) in patients with chronic inflammatory airway disease coexisting with chronic sinusitis. Here, PDE4A is linked to chronic rhinosinusitis.